Inspire Medical Systems (INSP) Receives Consensus Recommendation of “Hold” from Brokerages

Inspire Medical Systems (NASDAQ:INSP) has earned a consensus recommendation of “Hold” from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $41.63.

Several research firms recently commented on INSP. Dougherty & Co began coverage on Inspire Medical Systems in a research report on Tuesday, February 5th. They issued a “buy” rating and a $64.00 price target for the company. Zacks Investment Research lowered Inspire Medical Systems from a “buy” rating to a “hold” rating in a research report on Tuesday, March 5th.

In other Inspire Medical Systems news, CEO Timothy P. Herbert sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 15th. The shares were sold at an average price of $48.70, for a total value of $730,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Richard Buchholz sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, February 20th. The stock was sold at an average price of $56.87, for a total transaction of $113,740.00. The disclosure for this sale can be found here. In the last three months, insiders sold 1,067,054 shares of company stock valued at $55,571,457.



Hedge funds and other institutional investors have recently made changes to their positions in the business. Capital Financial Planning LLC bought a new stake in Inspire Medical Systems in the fourth quarter worth about $27,000. Arcadia Investment Management Corp MI bought a new stake in Inspire Medical Systems in the fourth quarter worth about $40,000. Great West Life Assurance Co. Can bought a new stake in shares of Inspire Medical Systems during the fourth quarter valued at approximately $50,000. Legal & General Group Plc raised its stake in shares of Inspire Medical Systems by 57.7% during the fourth quarter. Legal & General Group Plc now owns 1,843 shares of the company’s stock valued at $78,000 after acquiring an additional 674 shares in the last quarter. Finally, Cutler Group LP bought a new stake in shares of Inspire Medical Systems during the fourth quarter valued at approximately $92,000.

INSP traded down $1.60 on Monday, hitting $56.21. The company had a trading volume of 295,505 shares, compared to its average volume of 346,272. Inspire Medical Systems has a 12-month low of $22.50 and a 12-month high of $64.34.

Inspire Medical Systems (NASDAQ:INSP) last released its quarterly earnings results on Tuesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.10. The company had revenue of $16.56 million during the quarter, compared to analysts’ expectations of $15.42 million. The company’s quarterly revenue was up 66.3% compared to the same quarter last year.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

Featured Story: Producer Price Index (PPI)

Analyst Recommendations for Inspire Medical Systems (NASDAQ:INSP)

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.